Cargando…
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a rec...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724078/ https://www.ncbi.nlm.nih.gov/pubmed/26807072 http://dx.doi.org/10.1186/s12014-016-9103-3 |
_version_ | 1782411526702891008 |
---|---|
author | Morré, D. James Hostetler, Brandon Taggart, David J. Morré, Dorothy M. Musk, A. W. Robinson, Bruce W. S. Creaney, Jenette |
author_facet | Morré, D. James Hostetler, Brandon Taggart, David J. Morré, Dorothy M. Musk, A. W. Robinson, Bruce W. S. Creaney, Jenette |
author_sort | Morré, D. James |
collection | PubMed |
description | BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a recently identified marker of malignancy, were investigated using the ONCOblot tissue of origin cancer detection test. METHODS: Sequential serum samples collected from asbestos-exposed individuals prior to the development of frank mesothelioma were assayed for ENOX2 presence by 2-D gel immunoblot analysis to determine how long in advance of clinical symptoms mesothelioma-specific ENOX2 transcript variants could be detected. RESULTS: Two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4–10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years). Either one or both ENOX2 protein transcript variants indicative of malignant mesothelioma were absent in 14 of 15 subjects diagnosed with benign pleural plaques either with or without accompanying asbestosis. CONCLUSIONS: In a population of asbestos-exposed subjects who eventually developed malignant mesothelioma, ENOX2 protein transcript variants characteristic of malignant mesothelioma were present in serum 4–10 years in advance of clinical symptoms. As with all biomarker studies, these observations require validation in a larger, independent cohort of patients and should include prospective as well as retrospective sampling. |
format | Online Article Text |
id | pubmed-4724078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47240782016-01-24 ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms Morré, D. James Hostetler, Brandon Taggart, David J. Morré, Dorothy M. Musk, A. W. Robinson, Bruce W. S. Creaney, Jenette Clin Proteomics Research BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a recently identified marker of malignancy, were investigated using the ONCOblot tissue of origin cancer detection test. METHODS: Sequential serum samples collected from asbestos-exposed individuals prior to the development of frank mesothelioma were assayed for ENOX2 presence by 2-D gel immunoblot analysis to determine how long in advance of clinical symptoms mesothelioma-specific ENOX2 transcript variants could be detected. RESULTS: Two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4–10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years). Either one or both ENOX2 protein transcript variants indicative of malignant mesothelioma were absent in 14 of 15 subjects diagnosed with benign pleural plaques either with or without accompanying asbestosis. CONCLUSIONS: In a population of asbestos-exposed subjects who eventually developed malignant mesothelioma, ENOX2 protein transcript variants characteristic of malignant mesothelioma were present in serum 4–10 years in advance of clinical symptoms. As with all biomarker studies, these observations require validation in a larger, independent cohort of patients and should include prospective as well as retrospective sampling. BioMed Central 2016-01-22 /pmc/articles/PMC4724078/ /pubmed/26807072 http://dx.doi.org/10.1186/s12014-016-9103-3 Text en © Morré et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Morré, D. James Hostetler, Brandon Taggart, David J. Morré, Dorothy M. Musk, A. W. Robinson, Bruce W. S. Creaney, Jenette ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms |
title | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms |
title_full | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms |
title_fullStr | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms |
title_full_unstemmed | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms |
title_short | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms |
title_sort | enox2-based early detection (oncoblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724078/ https://www.ncbi.nlm.nih.gov/pubmed/26807072 http://dx.doi.org/10.1186/s12014-016-9103-3 |
work_keys_str_mv | AT morredjames enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms AT hostetlerbrandon enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms AT taggartdavidj enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms AT morredorothym enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms AT muskaw enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms AT robinsonbrucews enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms AT creaneyjenette enox2basedearlydetectiononcoblotofasbestosinducedmalignantmesothelioma410yearsinadvanceofclinicalsymptoms |